Results **1-100** of **38** for Criteria:**FP:(Bharat Biotech International Limited)** Office(s):**all** Language:**EN** Stemming: **true**

prev 1 next Page: 1 / 1 Go >

Refine Search FP:(Bharat Biotech International Limited) Search

Analysis

Sort by: Pub Date Desc View All **List Length** 100 **Machine translation**

No	Ctr	Title	PubDate	Int.Class	Appl.No	Applicant	Inventor
1.	WO	WO/2014/009971 - NON-ALCOHOLIC VACCINE COMPOSITIONS FREE FROM ANIMAL- ORIGIN AND PROCESS FOR PREPARATION THEREOF	16.01.2014	A61K 39/112	PCT/IN2013/000418	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy
Vaccine compositions and processes are disclosed for culturing the pathogenic bacteria containing virulent capsular polysaccharides in animal free culture medium, isolation, purification of polysaccharides and polysaccharide-protein conjugate. The purification of capsular polysaccharides may or may not employ alcohol for preparing immunogenic formulations. The immunogens obtained from the process of the invention were formulated and do not contain any sources of animal-origin and alcohol excipients. Also disclosed is a method for isolation, purification and conjugation of bacterial capsular polysaccharide of Haemophilus Influenza. The novel processes for purification, removal of endotoxin and formation of immuno-conjugates have also been used to generate novel compositions responsible to invoke immunogenicity against infections against Hib and prevention and treatment thereof.							
2.	WO	WO/2013/168182 - VACCINE COMBINATIONS	14.11.2013	A61K 39/295	PCT/IN2013/000306	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy
Vaccine combinations which comprise atleast two or more of the following antigens: DTap-HEV-HepB-HPV suitable for administration in humans. A number of variations in the combination of these antigens have been disclosed that is suitable for concomitant administration. The methods of preparing the vaccine combinations are disclosed. Nucleic acids encoding the antigens, as well as methods for their production and use are provided.							
3.	WO	WO/2013/160913 - ROTAVIRUS VACCINE COMPOSITIONS AND PROCESS FOR PREPARING THE SAME	31.10.2013	A61K 39/15	PCT/IN2013/000272	BHARAT BIOTECH INTERNATIONAL LIMITED	VADREVU, Krishna Mohan
Invention provides rotavirus vaccine compositions comprising rotavirus antigens, stabilizers and buffers. The buffers in the invention are pre-mixed in the rotavirus vaccine compositions to neutralize the high acidic pH of the stomach without, requiring separate administration of an antacid before vaccine administration. Vaccine compositions with buffers of the invention are stable liquid rotavirus vaccine formulations for oral administration.							
4.	US	20130280293 - COMBINATION HEPTAVALENT VACCINE	24.10.2013	A61K 39/295	13978397	Kuppuswamy Gopinathan	Kuppuswamy Gopinathan
The invention provides a stable immunogenic composition for prevention and prophylaxis of infections caused by rota virus, poliomyelitis virus, *Haemophilius influenza*, Hepatitis B, *Corynebacterium diphtheriae, Clostridium tetani, Bordatella pertusis* (acellular) in a single combined vaccine. The invention also provides for a bivalent immunogenic composition against rota virus and polio virus. The process of making such compositions of the multivalent antigens are also disclosed. The present invention also relates to the production and use of such vaccines for prophylaxis against the infections mentioned above.							
5.	US	20130272999 - Epidermal growth factor compositions	17.10.2013	A61K 38/18	13912103	Ella Krishna Murthy	Ella Krishna Murthy
A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.							
6.	JP	2013527229 - 局所適用のための新規な相乗作用的医薬組成物	27.06.2013	A61K 45/06	2013513041	バハラ バイオテック インターナショナル リミテッド	ヴァドレヴ クリシュナ モハン
創傷、熱傷創傷、植皮片、褥瘡及び糖尿病性足部潰瘍の予防及び治療用の局所製剤の調製のための新規な相乗作用的医薬組成物が開示される。相乗作用的組成物は、１又は２以上の殺菌薬及び静菌薬と併用してマイトジェニックタンパク質を含む。本発明におけるマイトジェニックタンパク質は、組換えヒト上皮増殖因子（Bharat Biotech International Limited社のｒｈ－ＥＧＦ）及び／又はｒｈ－ＰＤＧＦ－ＢＢのような任意の他の成長因子であり、前記殺菌薬及び静菌薬は、広域抗生物質スルファジアジン銀（ＳＳＤ）及びクロルヘキシジングルコン酸塩（glucomate）（ＣＨＧ）である。相乗作用的組成物に加えて、前記局所製剤は、基剤成分、担体、保存剤、乳化剤、皮膚軟化剤及び無痛化剤並びに１又は２以上の他の構成物も含む。前記新規な組成物は、より広範な抗菌薬適用範囲、ｒｈ－ＥＧＦによるＳＳＤの銀効果の逆転、熱傷創傷における銀耐性微生物に対する有効性、及びより優れた及びより迅速な創傷治癒等の相乗効果をもたらす。前記新規な組成物は、クリーム剤、ゲル剤又は液剤の形態で局所製剤を調製するために用いることができる。前記新規な製剤は、保存期間がより長く、貯蔵温度２－８℃で２年を超えて安定性がある。							

Sort by: Pub Date Desc View All **List Length** 100 Machine translation

No	Ctr	Title	PubDate	Int.Class	Appl.No	Applicant	Inventor
7.	EP	2575861 - A NOVEL SYNERGISTIC PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATIONS	10.04.2013	A61K 38/18	10782721	BHARAT BIOTECH INT LTD	VADREVU KRISHNA MOHAN
A novel synergistic pharmaceutical composition for preparation of topical formulations for prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers and diabetic foot ulcers is disclosed. The synergistic composition comprises a mitogenic protein in combination with one or more bactericidal and bacteriostatic agents. The mitogenic protein in the invention is Recombinant Human Epidermal Growth Factor (rh-EGF of Bharat Biotech International Limited) and /or any other growth factor like rh-PDGF-BB and the bactericidal and bacteriostatic agents are broad spectrum antibiotics silver sulfadiazine (SSD) and chlorhexidine glucomate (CHG). The topical formulations, in addition to the synergistic composition, also comprise base ingredients, carriers, preservatives, emulsifiers, skin. emollients and soothers and one or more other constituents. The novel composition results in synergistic effects like broader antibacterial coverage, reversal of silver effect of SSD by rh-EGF, effectiveness against silver resistant microorganisms in burn wounds, and better and faster wound healing. The novel composition may be used to prepare the topical formulations in the form of cream, gel or liquid. The novel formulations have longer shelf life and are stable for more than two years at the storage temperature of 2-8° degrees.						
8.	US	20130085103 - NOVEL SYNERGISTIC PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATIONS	04.04.2013	A61K 38/18	13701066	Mohan Vadrevu Krishna	Mohan Vadrevu Krishna
A synergistic pharmaceutical composition for the preparation of topical formulations for use in prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers, diabetic foot ulcers and other skin diseases is provided. The composition may include one or more synergistically active ingredients and one or more inactive ingredients. The synergistically active ingredients may include Recombinant Human Epidermal Growth Factor (rh-EGF) (REGEN-D™ of Bharat Biotech International Limited) and/or Platelet Derived Growth Factor (rh-PDGF-BB), silver sulfadiazine (SSD) and chlorhexidine gluconate (CHG). One or more inactive ingredients may comprise carriers, preservatives, emulsifiers, skin emollients and soothers and one or more other constituents.						
9.	CN	102939097 - 用于局部应用的新的协同药物组合物	20.02.2013	A61K 38/18	201080067208.5	巴拉特生物技术国际有限公司	克修拉·莫汉·威德麦都
公开了用于制备用于预防和治疗伤口、烧伤、皮移植片、压力性溃疡和糖尿病性足溃疡的局部制剂的新的协同药物组合物。所述协同组合物包括与一种或多种杀菌剂和抑菌剂组合的促细胞分裂蛋白。本发明中的促细胞分裂蛋白是重组人表皮生长因子(Bharat Biotech International Limited的rh-EGF)和/或任何其他生长因子，如rh-PDGF-BB，并且杀菌剂和抑菌剂是广谱抗生素磺胺嘧啶银(SSD)和葡萄糖酸氯己定(CHG)。除了协同组合物以外，局部制剂还包括基底成分、载体、防腐剂、乳化剂、润肤剂和柔肤剂以及一种或多种其他组分。新组合物产生协同效应，如更广的抗菌覆盖、通过rh-EGF逆转SSD的银效应、对抗烧伤中银抗性微生物的效力、以及更好且更快的伤口愈合。新组合物可用于制备用于乳膏、凝胶或液体形式的局部制剂。新制剂具有更长的贮存期限并且在2-8°C的贮存温度下稳定超过两年。						
10.	WO	WO/2012/172574 - VACCINE COMPOSITION COMPRISING AN INACTIVATED CHIKUNGUNYA VIRUS STRAIN	20.12.2012	A61K 39/12	PCT/IN2012/000432	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy
A vaccine composition for prophylaxis and treatment of Chikungunya virus infections is disclosed which is capable of conferring immunity against any genotypic variants of the Chikungunya virus. More particularly the invention discloses particular nucleotide sequences and their translated proteins thereof, which may be expressed as Virus Like Paricles which for use as a vaccine antigens against Chikungunya virus infections. The compositions disclosed in this invention are also protective against any genotypic variants of the Chikungunya virus which may be propagated by any suitable vector of the disease including Aedis albopictus and Aedis aegypti						
11.	BR	PI0610704 - COMPOSIÇÃO DO FATOR DE CRESCIMENTO EPIDÉRMICO, O PROCESSO PARA ISSO E SUA APLICAÇÃO	30.10.2012	A61K 9/00	PI0610704	Bharat Biotech International Limited	
COMPOSIÇÃO DO FATOR DE CRESCIMENTO EPIDÉRMICO, O PROCESSO PARA ISSO E SUA APLICAÇÃO. Uma composição para tratamento de uma ferida, onde a composição pode abranger quantidade terapeuticamente eficaz de um fator de crescimento epidérmico e um agente fisiologicamente aceitável, onde o agente fisiologicamente aceitável abrange, no mínimo, um estabilizador, um conservante, um agente de espessamento, transportador/diluente e, opcionalmente, agente regulador de PH e umectante.						
12.	BR	PI0711608 - COMPOSIÇÃO LIOFILIZADA, USO DE ANTÍGENO VIRAL, MÉTODO DE TRATAMENTO OU PREVENÇÃO DE VÍRUS ASSOCIADO, MÉTODO DE ADAPTAÇÃO DE UM VÍRUS DE UMA LINHAGEM CELULAR ADEQUADA	14.08.2012	A61K 39/15	PI0711608	Bharat Biotech International Limited	
COMPOSIÇAO LIOFILIZADA, USO DE ANTIGENO VIRAL, METODO DE TRATAMENTO OU PREVENÇÃO DE VÍRUS ASSOCIADO, METODO DE ADAPTAÇÁO DE UM VÍRUS DE UMA LINHAGEM CELULAR ADEQUADA. A presente invenção refere-se a uma composição compreendendo um antígeno viral, uma primeira proteína e uma segunda proteína. Opcionalmente, a composição igualmente compreende três díssacarideos diferentes, ou, opcionalmente, a composição compreende um açúcar primário e pelo menos um, preferivelmente dois açúcares secundários. A presente invenção igualmente refere-se ao uso de um antígeno viral, de uma primeira proteína e de uma segunda proteína para a fabricação de uma composição, preferivelmente uma vacina. A presente invenção, além disso, refere-se a um método de tratamento ou prevenção do vírus associado a doenças nos humanos. Além disso, a presente invenção refere-se a um método de adaptar um vírus a uma linhagem celular apropriada. A invenção é igualmente útil para a produção de suspensões de vírus apropriadas para fazer composições de vacinais de rotavírus estáveis, vivas/inatívadas, monovalentes e/ou polivalentes, líquidas/liofílizadas para meio de administração oral e/ou nasal ou qualquer outro meio apropriado em humano.						
13.	WO	WO/2012/093406 - A COMBINATION HEPTAVALENT VACCINE	12.07.2012	A61K 39/04	PCT/IN2012/000005	BHARAT BIOTECH INTERNATIONAL LIMITED	KUPPUSWAMY, Gopinathan
The invention provides a stable immunogenic composition for prevention and prophylaxis of infections caused by rota virus, poliomyelitis virus, Haemophilius influenza, Hepatitis B, Corynebacterium diphtheriae, Clostridium tetani, Bordatella pertusis (acellular) in a single combined vaccine. The invention also provides for a bivalent immunogenic composition against rota virus and polio virus. The process of making such compositions of the multivalent antigens are also disclosed. The present invention also relates to the production and use of such vaccines for prophylaxis against the infections mentioned above						
14.	WO	WO/2012/073257 - VACCINE FORMULATION FOR PROPHYLAXIS AND TREATMENT OF CHANDIPURA VIRUS INFECTIONS IN MAMMALS	07.06.2012	A61K 39/12	PCT/IN2011/000817	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy

Sort by: Pub Date Desc View All **List Length** 100 Machine translation

No	Ctr	Title	PubDate	Int.Class	Appl.No	Applicant	Inventor
The present invention is related to pharmaceutical formulations capable of eliciting protective immune response against Chandipura virus infection in humans and other mammalian hosts. The immunogenic formulation comprises Chandipura virus glycoprotein (G protein) and/or nucleoprotein expressed as recombinant proteins and purified from host cells. Vaccine compositions comprising the recombinant proteins elicit neutralizing antibodies similar to the vaccine compositions of purified inactivated Chandipura virus in a stable formulation. Methods of inactivating Chandipura virus for use as a candidate vaccine are disclosed. The vaccine compositions have been formulated with adjuvants to potentiate the immune response. The vaccine compositions disclosed in the invention are highly immunogenic and elicit protective immune response in mammalian host. The immunogenic compositions are formulated for in vivo administration to humans. The immunogenic preparation will also find use in diagnosing for the presence of the virus							
15.	WO	WO/2011/151835 - A NOVEL SYNERGISTIC PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATIONS	08.12.2011	A61K 38/18	PCT/IN2010/000468	BHARAT BIOTECH INTERNATIONAL LIMITED	VADREVU, Krishna Mohan
A novel synergistic pharmaceutical composition for preparation of topical formulations for prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers and diabetic foot ulcers is disclosed. The synergistic composition comprises a mitogenic protein in combination with one or more bactericidal and bacteriostatic agents. The mitogenic protein in the invention is Recombinant Human Epidermal Growth Factor (rh-EGF of Bharat Biotech International Limited) and /or any other growth factor like rh-PDGF-BB and the bactericidal and bacteriostatic agents are broad spectrum antibiotics silver sulfadiazine (SSD) and chlorhexidine glucomate (CHG). The topical formulations, in addition to the synergistic composition, also comprise base ingredients, carriers, preservatives, emulsifiers, skin. emollients and soothers and one or more other constituents. The novel composition results in synergistic effects like broader antibacterial coverage, reversal of silver effect of SSD by rh-EGF, effectiveness against silver resistant microorganisms in burn wounds, and better and faster wound healing. The novel composition may be used to prepare the topical formulations in the form of cream, gel or liquid. The novel formulations have longer shelf life and are stable for more than two years at the storage temperature of 2-8° degrees.							
16.	CA	2800417 - A PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION COMPRISING A MITOGENIC AGENT IN COMBINATION WITH ONE OR MORE BACTERICIDAL AND BACTERIOSTATIC AGENTS	08.12.2011	A61K 38/18	2800417	BHARAT BIOTECH INTERNATIONAL LIMITED	
A novel synergistic pharmaceutical composition for preparation of topical formulations for prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers and diabetic foot ulcers is disclosed. The synergistic composition comprises a mitogenic protein in combination with one or more bactericidal and bacteriostatic agents. The mitogenic protein in the invention is Recombinant Human Epidermal Growth Factor (rh-EGF of Bharat Biotech International Limited) and /or any other growth factor like rh-PDGF-BB and the bactericidal and bacteriostatic agents are broad spectrum antibiotics silver sulfadiazine (SSD) and chlorhexidine glucomate (CHG). The topical formulations, in addition to the synergistic composition, also comprise base ingredients, carriers, preservatives, emulsifiers, skin. emollients and soothers and one or more other constituents. The novel composition results in synergistic effects like broader antibacterial coverage, reversal of silver effect of SSD by rh-EGF, effectiveness against silver resistant microorganisms in burn wounds, and better and faster wound healing. The novel composition may be used to prepare the topical formulations in the form of cream, gel or liquid. The novel formulations have longer shelf life and are stable for more than two years at the storage temperature of 2-8° degrees.							
17.	BR	PI0613026 - COMPOSIÇÃO, FRAGMENTO DE NUCLEOTÍDEO, CONSTRUCTO DE DNA RECOMBINANTE, MÉTODO PARA PRODUZIR PROTEÍNA, COMPOSIÇÃO FARMACÊUTICA E MÉTODO PARA USO DA MESMA, FORMULAÇÃO, MÉTODO DE ADMINISTRAR COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE PREVENÇÃO E CONTROLE DE INFECÇÕES ASSOCIADAS A STAPHYLOCOCCUS	21.11.2011	A61K 39/085	PI0613026	Bharat Biotech International Limited	Kandaswamy Sumathy
COMPOSIÇÃO, FRAGMENTO DE NUCLEOTÍDEO, CONSTRUCTO DE DNA RECOMBINANTE, MÉTODO PARA PRODUZIR PROTEÍNA, COMPOSIÇÃO FARMACÊUTICA E MÉTODO PAPA USO DA MESMA, FORMULAÇÃO, MÉTODO DE ADMINISTRAR COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE PREVENÇÃO E CONTROLE DE INFECÇÕES ASSOCIADAS A STAPHYLOCOCCUS. A presente invenção descreve método de preparação e uso de formulação de vacina de polipetídeo para prevenção e controle de infecções mediadas por Staphylococcus em humanos, bovinos e outros mamíferos, usando tecnologia de DNA recombinante.							
18.	IL	209806 - VACCINE COMPOSITION USEFUL FOR HPV AND HEPATITIS B INFECTIONS AND A METHOD FOR PREPARING THE SAME	28.02.2011	A61K /	209806	BHARAT BIOTECH INTERNATIONAL LIMITED	
19.	WO	WO/2011/007363 - A COMPOSITION USEFUL AS ROTAVIRUS VACCINE AND A METHOD THEREFOR.	20.01.2011	A61K 39/15	PCT/IN2010/000041	BHARAT BIOTECH INTERNATIONAL LIMITED	VADREVU, Krishna, Mohan
Compositions and methods related to live or live attenuated pre-conditioned and typical viruses such as rotaviruses are disclosed. The live attenuated rotaviruses exhibit better stability characteristics and are useful for the prevention of a rotavirus infection and/or rotavirus gastroenteritis in children.							
20.	WO	WO/2010/143194 - STABLE IMMUNOGENIC PROTEIN HAVING MULTIPLE CYSTEINES MOLECULES PROCESS THEREFOR AND COMPOSITION THEREOF	16.12.2010	C07K 14/445	PCT/IN2009/000417	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy
The invention describes a stable immunogenic protein having multiple cysteines molecules wherein the protein is having stability up to two years and purity more than 98% particularly rPvRII and/or rPfF2. It also discloses a method for producing said immunogenic protein comprising the following steps: culturing the host E.coli cells containing a desired recombinant gene construct comprising a codon optimized gene sequence of rPvRII and/or rPfF2 to produce cells in high density; inducing expression rPvRII and/or rPfF2 as inclusion bodies; harvesting the cells and isolating the said inclusion bodies; separating rPvRII and/or rPfF2 from inclusion bodies by repeated sequential washing and solubilizing with chaotrophic agents comprising guanidine hydrochloride and / or urea; purifying the protein by subjecting to metal-chelate affinity chromatography; re-folding of the purified rPvRII and/or rPfF2 obtained in step e) with a redox system to recover a high yield of the soluble protein, followed by further purifying the desired protein by removing impurities by subjecting to chromatography. Further the invention discloses formulation comprising rPvRII or rPfF2, preferably being lyophilized using polysaccharides preferably sucrose, lactose, and pharmaceutically acceptable adjuvants such as aluminum hydroxide, aluminum phosphate, CpG nucleotides, non-CpG nucleotides, Montanide ISA-720, MF-59, Mono- phosphoryl Lipid-A (MPL-A) and QS-21.							
21.	US	20100173842 - VACCINE FOR STAPHYLOCOCCAL INFECTIONS	08.07.2010	A61K 38/16	12575667	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA Krishna Murthy

Sort by: Pub Date Desc View All **List Length** 100 Machine translation

No	Ctr	Title	PubDate	Int.Class	Appl.No	Applicant	Inventor
		The invention relates to a method of preparation and use of a polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology.					
22.	US	20100015123 - NOVEL THROMBOLYTIC MOLECULES AND A PROCESS THEREFOR	21.01.2010	A61K 38/43	12300150	BHARAT BIOTECH INTERNATIONAL LIMITED	Ella Krishna Murthy
		New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.					
23.	WO	WO/2010/001409 - VACCINE COMPOSITION USEFUL FOR HPV AND HEPATITIS B INFECTIONS AND A METHOD FOR PREPARING THE SAME	07.01.2010	A61K 39/12	PCT/IN2009/000333	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna, Murthy
		The invention describes a vaccine compositions comprising chimeric fusions of the HPV antigens with viral or bacterial proteins conferring enhanced immunogenicity useful for Hepatitis B virus as well as human papillomavirus (HPV) infections.					
24.	US	20090220538 - VACCINE FOR STAPHYLOCOCCAL INFECTIONS	03.09.2009	A61K 39/085	12067458	BHARAT BIOTECH INTERNATIONAL LIMITED	Ella Krishna Murthy
		The present invention describes method of preparation and use of polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology.					
25.	MX	MX/a/2008/014391 - A COMPOSITION USEFUL AS A VACCINE	13.05.2009	A61K 39/15	MX/a/2008/014391	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy
		The present invention relates to a composition comprising a viral antigen, a first protein and a second protein. Optionally, the composition also comprises three different disaccharaides, or, optionally, the composition comprises a primary sugar and at least one, preferably two secondary sugars. The present invention also relates to the use of a viral antigen, a first protein and a second protein for the manufacture of a composition, preferably a vaccine. The present invention furthermore relates to a method of treatment or prevention of virus associates diseases in humans. Moreover, the present invention relates to a method of adapting a virus to a suitable cell-line. The invention is also useful for the production of virus suspensions suitable for making stable, live/inactivated, monovalent and/or polyvalent, liquid/lyophilized rotavirus vaccine compositions for oral and/or nasal or any other suitable route of administration in human.					
26.	US	20080311216 - Methods for treating a wound using epidermal growth factor formulation	18.12.2008	A61K 38/18	11915727	Ella Krishna Murthy	Ella Krishna Murthy
		A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.					
27.	WO	WO/2008/026225 - A VACCINE FOR CHIKUNGUNYA VIRUS INFECTION	06.03.2008	A61K 39/12	PCT/IN2007/000383	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna, Murthy
		The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikungunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikungunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus.					
28.	US	20070275006 - IRIDOID GLYCOSIDE COMPOSITION	29.11.2007	A61K 45/00	11683975	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH	Khajuria Anamika
		The present invention relates to an adjuvants, particularly to the use of a well-characterized plant based iridoid glycoside adjuvant from plant *Picrorhiza kurroa*, acting as an adjuvant against T-dependent antigen and specifically against HBsAg and typhoid antigens. The present invention also relates to the method of producing the iridoid glycoside adjuvant and the products utilizing such adjuvants for induction of cellular immunity. The adjuvants may be used alone or with specific antigens. The two antigens used in the study represents HBsAg, a recombinant antigen expressed in *Pichia pastoris*, and typhoid Vi polysaccharide purified from *Salmonella typhi* broth. These antigens are studied for their immunogenicity with the adjuvant iridoid glycoside adjuvant					
29.	WO	WO/2007/132480 - A COMPOSITION USEFUL AS A VACCINE	22.11.2007	A61K 39/15	PCT/IN2007/000190	BHARAT BIOTECH INTERNATIONAL	ELLA, Krishna, Murthy

Sort by: Pub Date Desc View All **List Length** 100 **Machine translation**

No	Ctr	Title	PubDate	Int.Class	Appl.No	Applicant	Inventor
						LIMITED	
The present invention relates to a composition comprising a viral antigen, a first protein and a second protein. Optionally, the composition also comprises three different disaccharaides, or, optionally, the composition comprises a primary sugar and at least one, preferably two secondary sugars. The present invention also relates to the use of a viral antigen, a first protein and a second protein for the manufacture of a composition, preferably a vaccine. The present invention furthermore relates to a method of treatment or prevention of virus associates diseases in humans. Moreover, the present invention relates to a method of adapting a virus to a suitable cell-line. The invention is also useful for the production of virus suspensions suitable for making stable, live/inactivated, monovalent and/or polyvalent, liquid/lyophilized rotavirus vaccine compositions for oral and/or nasal or any other suitable route of administration in human.							
30.	WO	WO/2007/132481 - NOVEL THROMBOLYTIC MOLECULES AND A PROCESS THEREFOR	22.11.2007	C07K 14/31	PCT/IN2007/000191	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna, Murthy
The invention discloses a new THROMBOLYTIC protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and is suitable to their variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The invention discloses the design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.							
31.	WO	WO/2007/007352 - A VACCINE FOR STAPHYLOCOCCAL INFECTIONS	18.01.2007	C07K 14/31	PCT/IN2006/000246	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna, Murthy
The present invention describes method of preparation and use of polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology.							
32.	KR	1020060132590 - A PROCESS FOR THE PREPARATION AND PURIFICATION OF RECOMBINANT PROTEINS	21.12.2006	C07K 1/14	1020067010166	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA KRISHNA MURTHY
A novel process for the purification of recombinant protein expressed as protein or particle is herewith described. In this purification process, the protein is purified by hydrophobic interaction. The interaction of this protein step resulted in an increase in recovery and purity from 15%-80%. The protein further purified has its application in vaccines and pharmaceuticals. © KIPO & WIPO 2007							
33.	WO	WO/2006/126212 - EPIDERMAL GROWTH FACTOR COMPOSITION, A PROCESS THEREFOR AND ITS APPLICATION	30.11.2006	A61K 9/00	PCT/IN2006/000168	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna, Murthy
A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.							
34.	WO	WO/2006/021965 - EUKARYOTIC BASED SYNERGISTIC FORMULATION FOR GASTRO-INTESTINAL DISORDERS	02.03.2006	A61K 36/062	PCT/IN2004/000256	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna, Murthy
The present invention describes a eukaryotic based synergistic formulation for gastro-intestinal disorders comprising eukaryotics and adjuncts selected from pharmaceutically and or physiologically acceptable components. The invention also describes the manner in which the eukaryotics are isolated from tropical fruits , The medium used for growing them and the method used to convert the formulation to dispensable forms. The medium comprising Glucose for carbon source, soybean casein dextrose medium (SCDM) for Nitrogen source, MgSo4, KCl, NaCl, (NH)4HPO4 and with microelements like MnSO4, FeSO4, CuSO4, Boric acid and Vitamins, D-Biotin and thiamine HCl ranging from 0.001% to 0.6% and designated as BBIL-SB. The formulation can be effectively used to prevent and or cure gastro intestinal disorders by administering in various forms to the mammals including human suffering there from, in a required quantity.							
35.	WO	WO/2005/070454 - A NOVEL PROCESS OF HEPATITIS A VACCINE PREPARATION	04.08.2005	A61K 39/29	PCT/IN2005/000020	BHARAT BIOTECH INTERNATIONAL LIMITED	CHITAMBER, Shobha, Dattatraya
An Indian isolate of Hepatitis A virus- NIVIN97 has been isolated, adapted to tissue culture, characterized and further propagated using Vero and MRC-5 cell lines for vaccine preparation. The method involves the cell culture adaptation of the virus isolate from clinical sample (faecal) in BGMK cell line initially , characterization of the virus and further adaptation to Vero and MRC-5 cells , scale-up ,inactivation and down stream processing method of the inactivated viral antigens for the preparation of an inactivated vaccine.							
36.	WO	WO/2005/063794 - A PROCESS FOR THE PREPARATION AND PURIFICATION OF RECOMBINANT PROTEINS	14.07.2005	C07K 1/36	PCT/IN2004/000257	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna, Murthy
A novel process for the purification of recombinant protein expressed as protein or particle is herewith described. In this purification process, the protein is purified by hydrophobic interaction. The interaction of this protein step resulted in an increase in recovery and purity from 15%-80%. The protein further purified has its application in vaccines and pharmaceuticals.							
37.	CA	2548378 - A PROCESS FOR THE PREPARATION AND PURIFICATION OF RECOMBINANT PROTEINS	14.07.2005	C07K 1/30	2548378	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, KRISHNA MURTHY

Sort by: Pub Date Desc View All **List Length** 100 **Machine translation**

No	Ctr	Title	PubDate	Int.Class	Appl.No	Applicant	Inventor
A novel process for the purification of recombinant protein expressed as protein or particle is herewith described. In this purification process, the protein is purified by hydrophobic interaction. The interaction of this protein step resulted in an increase in recovery and purity from 15%-80%. The protein further purified has its application in vaccines and pharmaceuticals.							
38.	US	6897041 - Expression of recombinant mature lysostaphin	24.05.2005	C12N 9/52	10110795	Bharat Biotech International Limited	Khatri Ghan Shyam
A portion of the lysostaphin gene of *Staphylococcus simulans* has been cloned and overexpressed in the cytoplasm of *E. coli* to yield lysostaphin, in the absence of preprolysostaphin and prolysostaphin, under the transcriptional control of an IPTG-inducible promoter and a ribosome binding site. IPTG induction of the transformed host cells produces intracellular, soluble, mature lysostaphin (27 kDa), in the complete absence of preprolysostaphin and prolysostaphin. The mature lysostaphin so formed dose not require post-translational modification. The mature lysostaphin so formed can be used treat and prevent *staphylococcal* infections.							

Results **1-100** of **38** for Criteria:**FP:(Bharat Biotech International Limited)** Office(s):**all** Language:**EN** Stemming: **true**

prev 1 next

Refine Search FP:(Bharat Biotech International Limited) Search